Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leader in molecular imaging technology and services, today announced the sale of four (4) PET-CT 64-slice scanners, along with ...

A newer type of prostate cancer scan called 64 Cu-SAR-bisPSMA found more than twice as many cancer spots as a commonly used PSMA PET scan in men whose prostate-specific antigen (PSA) was rising after ...

PET-based imaging study designed to assess the biodistribution of CIT-013 and associate disease activity with CIT-013 target disposition in ...

PET scans may serve as both a diagnostic and prognostic tool in giant cell arteritis (GCA), according to a new study. In over 100 patients with GCA who underwent 18 F-fluorodeoxyglucose (FDG) PET ...

Positron emission tomography (PET) is an imaging modality to better understand the pathophysiology of a disease at molecular level and typically referred to as molecular imaging. It reveals the ...

Professor of Medical Imaging at the University of Arizona Lars Furenlid, the project’s lead researcher. Professor of Radiology at UMass Chan Medical School Michael King. In order to better study and ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

The Centers for Medicare & Medicaid Services (CMS) has expanded coverage of brain amyloid positron-emission tomography (PET) imaging for the diagnosis of Alzheimer's disease (AD). The CMS decision, ...

It is difficult to escape a genitourinary malignancies session at any major oncology meeting these days without hearing a proclamation that the technetium-99 (Tc99) bone scan is dead. The triumphant ...

PET-CT imaging with [18 F]fluorodeoxyglucose (FDG) and [18 F]fluorocholine (FCH) altered treatment plans in only a tiny minority of patients undergoing initial staging for hepatocellular carcinoma ...